Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease

Recruitment Status
COMPLETED - HAS RESULTS
(See Contacts and Locations)Verified May 2019 by Imperial College London
Sponsor
Imperial College London
Information Provided by (Responsible Party)
Imperial College London
Clinicaltrials.gov Identifier
NCT00802529
Other Study ID Numbers:
CRO1135
First Submitted
December 3, 2008
First Posted
December 4, 2008
Results First Posted
May 8, 2016
Last Update Posted
June 26, 2019
Last Verified
May 2019

ClinicalTrials.gov processed this data on June 2019Link to the current ClinicalTrials.gov record .

History of Changes

Study Details

Study Description

Meniere's disease is characterised by episodic spontaneous vertigo attacks with hearing loss, ringing sounds and fullness in the ear. In one out of five patients, standard first line medical treatment is not effective in controlling vertigo attacks. For these incapacitated patients, gentamicin injections through the ear drum is a well established minimally invasive treatment. Major surgery of the balance organs or nerve, risking complete hearing loss, CSF leak, meningeal infections, are rarely performed nowadays. Gentamicn is very effective in controlling vertigo and acts by chemical ablation of end organs. As hearing and balance organs are entwined around each other, gentamicin treatment does not come without the risk of hearing loss. In fact, meta-analysis shows hearing deterioration in 13% to 35% percent of gentamicin treated patients. On the other hand, steroids are drug of choice for autoimmune inner ear disease and commonly used for sudden hearing loss. They are non toxic drugs without any known side effects during local treatment in ear. We will compare the two in this randomised, double blind trial.

Condition or DiseaseIntervention/Treatment
Meniere's Disease
Drug: MethylprednisoloneDrug: Gentamicin

Study Design

Study TypeInterventional
Actual Enrollment60 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingQuadruple
Primary PurposeTreatment
Official TitleEffectiveness of Transtympanic Steroids in Unilateral Ménière's Disease: a Randomised Controlled Double-Blind Trial
Study Start DateMarch 31, 2009
Actual Primary Completion DateApril 30, 2015
Actual Study Completion DateApril 30, 2015

Groups and Cohorts

Group/CohortIntervention/Treatment
Steroid (Methylprednisolone)
Steroid (Methylprednisolone)
Drug: Methylprednisolone
2 transtympanic injections at interval of two weeks.
Gentamicin
Gentamicin
Drug: Gentamicin
2 transtympanic injections at an interval of two weeks. If there is significant hearing loss before second injection, it will be replaced by normal saline in double blinded fashion.

Outcome Measures

Primary Outcome Measures
  1. Vertigo Attacks
    The number of vertigo attacks between 18-24months follow-up were taken retrospectively during a face-to-face appointment at 24 months follow-up and compared to 6 month pre-enrollment baseline (as per Committee on Hearing and Equilibrium guidelines).
Secondary Outcome Measures
  1. Change in Hearing
    Hearing was measured as ipsilesional pure-tone threshold at Baseline, 1month, 2months, 6months, 12month, 18months and 24 months follow-up. Hearing level was taken as the average threshold across 0.5, 1, 2 and 3KHz.
  2. Change in Speech Discrimination
    Speech discrimination was measured at Baseline, 1month, 2months, 6months, 12month and 24 months follow-up. Speech discrimination was assessed by means of ipsilesional suprathreshold word recognition (%). Arthur Boothroyd's isophonemic word lists (AB wordlists, Guymark, Southampton) comprising sets of 10 words were played to the ipsilesional ear at the low-frequency pure-tone threshold of 0·5, 1 and 2 kHz +30dB with masking sound in the contralesional ear if necessary. The formula for masking level was: low-frequency pure-tone threshold in ipsilesional ear - bone conduction mean threshold (0·5, 1 and 2KHz) in contralesional ear - 40dB. Speech loudness and masking were rounded to the nearest 5dB. Step increments and decrements of 10dB for speech loudness and masking were used to attain the maximum speech discrimination score.

Eligibility Criteria

Ages Eligible for Study(Adult, Older Adult)
Sexes Eligible for StudyAll
Accepts Healthy VolunteersNo
Inclusion Criteria
Patients with unilateral Ménière's disease (definite or probable, according to Committee on Hearing and Equilibrium guidelines, 1995) with hearing loss and presenting with recurrent vertigo, not responding to medical treatment for at least 6 months will be included. There should be normal, age appropriate hearing in the contralateral ear.
Exclusion Criteria
Patients with Ménière's disease in later stages (not having vertigo attacks).
Age: patients older than 70 years at the start of the trial.
Severe disability (e.g. neurological, orthopaedic, cardiovascular) or serious concurrent illness that might interfere with treatment or follow up.
Active additional neuro-otological disorders that may mimic Ménière's disease (e.g. vestibular migraine, vertebro-basilar TIAs, acoustic neuroma) and thus will make the objective follow up difficult.
Concurrent ear pathology that may interfere with transtympanic treatment (e.g. active middle ear disease).
Family history of unexplained deafness (possibility of genetic susceptibility to gentamicin toxicity).
History of known adverse/allergic reaction to steroids or gentamicin.

Contacts and Locations

Sponsors and CollaboratorsImperial College London
Locations
Imperial college Healthcare NHS Trust | London , United Kingdom,
Investigators
Principal Investigator: Adolfo M Bronstein, PhD, FRCP, Imperial College London